PL2797921T3 - Skondensowane tetra- lub penta-cykliczne dihydrodiazepinokarbazolony jako inhibitory PARP - Google Patents
Skondensowane tetra- lub penta-cykliczne dihydrodiazepinokarbazolony jako inhibitory PARPInfo
- Publication number
- PL2797921T3 PL2797921T3 PL11878508T PL11878508T PL2797921T3 PL 2797921 T3 PL2797921 T3 PL 2797921T3 PL 11878508 T PL11878508 T PL 11878508T PL 11878508 T PL11878508 T PL 11878508T PL 2797921 T3 PL2797921 T3 PL 2797921T3
- Authority
- PL
- Poland
- Prior art keywords
- penta
- parp inhibitors
- dihydrodiazepinocarbazolones
- cyclic
- fused tetra
- Prior art date
Links
- 239000012661 PARP inhibitor Substances 0.000 title 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2011/085148 WO2013097225A1 (en) | 2011-12-31 | 2011-12-31 | Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors |
| EP11878508.8A EP2797921B1 (en) | 2011-12-31 | 2011-12-31 | Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2797921T3 true PL2797921T3 (pl) | 2018-02-28 |
Family
ID=48696280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11878508T PL2797921T3 (pl) | 2011-12-31 | 2011-12-31 | Skondensowane tetra- lub penta-cykliczne dihydrodiazepinokarbazolony jako inhibitory PARP |
Country Status (29)
| Country | Link |
|---|---|
| US (4) | US9260440B2 (enExample) |
| EP (2) | EP2797921B1 (enExample) |
| JP (1) | JP6034877B2 (enExample) |
| KR (1) | KR101716012B1 (enExample) |
| CN (2) | CN103703004B (enExample) |
| AU (1) | AU2011384858B2 (enExample) |
| BR (1) | BR112014012628B8 (enExample) |
| CA (1) | CA2856309C (enExample) |
| CY (1) | CY1119804T1 (enExample) |
| DK (1) | DK2797921T3 (enExample) |
| EA (1) | EA027533B1 (enExample) |
| ES (1) | ES2645814T3 (enExample) |
| HR (1) | HRP20171883T1 (enExample) |
| HU (1) | HUE035153T2 (enExample) |
| IL (1) | IL233365A (enExample) |
| IN (1) | IN2014DN06169A (enExample) |
| LT (1) | LT2797921T (enExample) |
| ME (1) | ME02855B (enExample) |
| MX (1) | MX353578B (enExample) |
| NO (1) | NO2797921T3 (enExample) |
| NZ (1) | NZ624063A (enExample) |
| PL (1) | PL2797921T3 (enExample) |
| PT (1) | PT2797921T (enExample) |
| RS (1) | RS56616B1 (enExample) |
| SG (1) | SG11201401726VA (enExample) |
| SI (1) | SI2797921T1 (enExample) |
| SM (1) | SMT201700543T1 (enExample) |
| WO (1) | WO2013097225A1 (enExample) |
| ZA (1) | ZA201405560B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME02855B (me) | 2011-12-31 | 2018-04-20 | Beigene Ltd | KONDENZOVANI TETRA ILl PENTA-CIKLIČNI DIHIDRODIAZEPINOKARBAZOLONI KAO PARP INHIBITORI |
| RU2696572C2 (ru) | 2012-03-07 | 2019-08-05 | Инститьют Оф Кансер Ресёрч: Ройял Кансер Хоспитал (Зе) | 3-арил-5-замещенные соединения изохинолин-1-она и их терапевтическое применение |
| CN105722835B (zh) | 2013-09-11 | 2018-07-31 | 癌症研究协会:皇家癌症医院 | 3-芳基-5-取代的-异喹啉-1-酮化合物及它们的疗法应用 |
| IL257442B2 (en) * | 2015-08-25 | 2023-03-01 | Beigene Ltd | Process for preparing parp inhibitor, crystalline forms and their uses |
| IL285318B (en) * | 2016-04-01 | 2022-09-01 | Kalyra Pharmaceuticals Inc | Estrogen receptor modulators |
| CN110087730B (zh) * | 2016-09-27 | 2023-03-28 | 百济神州(苏州)生物科技有限公司 | 使用包含parp抑制剂的组合产品治疗癌症 |
| WO2018157794A1 (en) * | 2017-02-28 | 2018-09-07 | Beigene, Ltd. | Crystalline forms of salts of fused tera or penta-cyclic dihydrodiazepinocarazolones, and uses thereof |
| CN106883232B (zh) | 2017-03-31 | 2019-01-22 | 苏州康润医药有限公司 | 一种氮杂非那烯-3-酮的衍生物及其制备方法与应用 |
| TW201908317A (zh) * | 2017-07-17 | 2019-03-01 | 開曼群島商百濟神州有限公司 | 使用parp抑制劑、替莫唑胺及/或放射療法的組合治療癌症 |
| AU2019275722A1 (en) * | 2018-06-01 | 2020-11-12 | Beigene, Ltd. | Maintenance therapy of a PARP inhibitor in treating gastric cancer |
| CN111171031B (zh) * | 2019-05-10 | 2021-04-09 | 百济神州(苏州)生物科技有限公司 | 一种含parp抑制剂倍半水合物产物的制备方法 |
| CN111171002B (zh) * | 2019-05-16 | 2021-04-06 | 百济神州(苏州)生物科技有限公司 | 一种parp抑制剂中间体的制备方法 |
| JP2022534093A (ja) | 2019-05-31 | 2022-07-27 | ベイジーン リミテッド | Ｐａｒｐ阻害剤ペレット製剤及びその調製方法 |
| JP2022543832A (ja) | 2019-08-06 | 2022-10-14 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | 変異体を治療するためのエストロゲン受容体調節剤 |
| WO2021046014A1 (en) | 2019-09-03 | 2021-03-11 | Teva Czech Industries S.R.O | Solid state forms of pamiparib and process for preparation thereof |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE445326B (sv) | 1983-04-05 | 1986-06-16 | Malmstroem Anders E H | Sett och anordning for forhindrande av veggturbulens |
| US6799298B2 (en) | 1998-03-11 | 2004-09-28 | Overture Services, Inc. | Technique for locating an item of interest within a stored representation of data |
| PL210415B1 (pl) | 1999-01-11 | 2012-01-31 | Agouron Pharma | Pochodne indolu, środek farmaceutyczny i zastosowanie pochodnych indolu |
| US6887996B2 (en) | 2000-12-01 | 2005-05-03 | Guilford Pharmaceuticals Inc. | Compounds and their use |
| US6423705B1 (en) | 2001-01-25 | 2002-07-23 | Pfizer Inc. | Combination therapy |
| US6906096B2 (en) | 2002-06-28 | 2005-06-14 | Irm Llc | 4,7-Disubstituted indoles and methods of making |
| SI1585749T1 (sl) | 2003-01-09 | 2008-10-31 | Pfizer | Derivati diazepinoindola kot inhibitorji kinaze |
| AU2004242947B2 (en) | 2003-05-28 | 2010-04-29 | Eisai Inc. | Compounds, methods and pharmaceutical compositions for inhibiting PARP |
| CA2648369A1 (en) | 2006-04-04 | 2007-10-11 | Pfizer Products Inc. | Polymorphic forms of (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4?l)-1-oxo-2,6-dihydro-1h-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide |
| AU2007232279B2 (en) | 2006-04-04 | 2010-05-06 | Pfizer Products Inc. | Combination therapy of (2R)-2-amino-2-cyclohexyl-N-(2-(1-methyl-1H-pyrazol-4-yl)-6- oxo-5,6-dihydro-1H-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide |
| EP2220073B1 (en) | 2007-11-15 | 2014-09-03 | MSD Italia S.r.l. | Pyridazinone derivatives as parp inhibitors |
| CN104478875B (zh) | 2008-08-06 | 2017-04-12 | 麦迪韦逊科技有限公司 | 聚(adp‑核糖)聚合酶(parp)的二氢吡啶并酞嗪酮抑制剂 |
| WO2011130661A1 (en) | 2010-04-16 | 2011-10-20 | Biomarin Pharmaceutical Inc. | Methods of using dihydropyridophthalazinone inhibitors of poly (adp-ribose)polymerase (parp) |
| ME02855B (me) | 2011-12-31 | 2018-04-20 | Beigene Ltd | KONDENZOVANI TETRA ILl PENTA-CIKLIČNI DIHIDRODIAZEPINOKARBAZOLONI KAO PARP INHIBITORI |
| EP3044234B9 (en) | 2013-09-13 | 2020-08-26 | BeiGene Switzerland GmbH | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
| TWI726608B (zh) | 2014-07-03 | 2021-05-01 | 英屬開曼群島商百濟神州有限公司 | 抗pd-l1抗體及其作為治療及診斷之用途 |
| US9637488B2 (en) | 2015-01-29 | 2017-05-02 | Fuqiang Ruan | Heterocyclic compounds as inhibitors of class I PI3KS |
| IL257442B2 (en) | 2015-08-25 | 2023-03-01 | Beigene Ltd | Process for preparing parp inhibitor, crystalline forms and their uses |
| CN110087730B (zh) | 2016-09-27 | 2023-03-28 | 百济神州(苏州)生物科技有限公司 | 使用包含parp抑制剂的组合产品治疗癌症 |
| WO2018157794A1 (en) | 2017-02-28 | 2018-09-07 | Beigene, Ltd. | Crystalline forms of salts of fused tera or penta-cyclic dihydrodiazepinocarazolones, and uses thereof |
| TW201908317A (zh) | 2017-07-17 | 2019-03-01 | 開曼群島商百濟神州有限公司 | 使用parp抑制劑、替莫唑胺及/或放射療法的組合治療癌症 |
-
2011
- 2011-12-31 ME MEP-2017-278A patent/ME02855B/me unknown
- 2011-12-31 WO PCT/CN2011/085148 patent/WO2013097225A1/en not_active Ceased
- 2011-12-31 AU AU2011384858A patent/AU2011384858B2/en not_active Ceased
- 2011-12-31 HU HUE11878508A patent/HUE035153T2/en unknown
- 2011-12-31 KR KR1020147018104A patent/KR101716012B1/ko active Active
- 2011-12-31 ES ES11878508.8T patent/ES2645814T3/es active Active
- 2011-12-31 EP EP11878508.8A patent/EP2797921B1/en active Active
- 2011-12-31 US US14/369,374 patent/US9260440B2/en active Active
- 2011-12-31 NO NO11878508A patent/NO2797921T3/no unknown
- 2011-12-31 CA CA2856309A patent/CA2856309C/en active Active
- 2011-12-31 EA EA201491303A patent/EA027533B1/ru not_active IP Right Cessation
- 2011-12-31 BR BR112014012628A patent/BR112014012628B8/pt not_active IP Right Cessation
- 2011-12-31 NZ NZ624063A patent/NZ624063A/en not_active IP Right Cessation
- 2011-12-31 CN CN201180072418.8A patent/CN103703004B/zh active Active
- 2011-12-31 JP JP2014549295A patent/JP6034877B2/ja not_active Expired - Fee Related
- 2011-12-31 MX MX2014007840A patent/MX353578B/es active IP Right Grant
- 2011-12-31 PL PL11878508T patent/PL2797921T3/pl unknown
- 2011-12-31 PT PT118785088T patent/PT2797921T/pt unknown
- 2011-12-31 LT LTEP11878508.8T patent/LT2797921T/lt unknown
- 2011-12-31 SM SM20170543T patent/SMT201700543T1/it unknown
- 2011-12-31 SG SG11201401726VA patent/SG11201401726VA/en unknown
- 2011-12-31 SI SI201131351T patent/SI2797921T1/en unknown
- 2011-12-31 IN IN6169DEN2014 patent/IN2014DN06169A/en unknown
- 2011-12-31 DK DK11878508.8T patent/DK2797921T3/en active
- 2011-12-31 RS RS20171228A patent/RS56616B1/sr unknown
- 2011-12-31 HR HRP20171883TT patent/HRP20171883T1/hr unknown
- 2011-12-31 EP EP17183473.2A patent/EP3315500B1/en active Active
- 2011-12-31 CN CN201610603192.4A patent/CN106220635B/zh active Active
-
2014
- 2014-06-25 IL IL233365A patent/IL233365A/en active IP Right Grant
- 2014-07-28 ZA ZA2014/05560A patent/ZA201405560B/en unknown
-
2016
- 2016-01-05 US US14/988,484 patent/US9617273B2/en not_active Expired - Fee Related
-
2017
- 2017-04-05 US US15/479,958 patent/US10112952B2/en active Active
- 2017-11-16 CY CY20171101198T patent/CY1119804T1/el unknown
-
2018
- 2018-09-19 US US16/135,512 patent/US10501467B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL233366A (en) | Tetra- or phentocyclo-pyridopathalazines are digested as parp inhibitors | |
| ZA201405560B (en) | Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors | |
| IL227252A0 (en) | Aminodihydrothiazine history from sisterhood | |
| GB201101140D0 (en) | Fused aminodihydrothiazine derivatives | |
| HUE048834T2 (hu) | Kináz inhibitorok | |
| ZA201404156B (en) | Kinase inhibitors | |
| AU341795S (en) | Paver | |
| IL229028A0 (en) | Kinase inhibitors | |
| EP2680844A4 (en) | AMINOCHINOLINE AS A KINASEHEMMER | |
| AP3529A (en) | Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors | |
| ZA201409497B (en) | Tetrahydroquinazolinone derivatives as parp inhibitors | |
| ZA201407904B (en) | Nampt inhibitors | |
| ZA201404157B (en) | Kinase inhibitors | |
| EP2847186A4 (en) | SUBSTITUTED AMINOCHINAZOLINES USE AS CHINESE HEMMER | |
| IL235919A0 (en) | inhibitors of fbxo3 | |
| PL2599920T3 (pl) | Wykańczarka | |
| GB201113689D0 (en) | Novel PDE4 inhibitors | |
| GB201120494D0 (en) | Modified exonuclease | |
| GB201100924D0 (en) | Surfaces | |
| GB201116360D0 (en) | Glycobiological surfaces | |
| GB201110249D0 (en) | Laser | |
| ZA201308697B (en) | Hydroxymethylaryl-substituted pyprolotriazines as alk1 inhibitors | |
| GB201120474D0 (en) | Inhibitors | |
| GB201100183D0 (en) | Fused aminodihydropyrimidone derivatives | |
| GB201219306D0 (en) | Nampt inhibitors |